Lethal T-cell lymphoma identified in one patient who received axicabtagene ciloleucel therapy for diffuse large B-cell lymphoma<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, June 14, 2024 (HealthDay News) — Second tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England Journal of Medicine<\/em>.<\/p>\n Mark P. Hamilton, M.D., Ph.D., from Stanford University in California, and colleagues examined the occurrence of second tumors after CAR T-cell therapy since 2016. A broad array of molecular, genetic, and cellular techniques were used to interrogate the tumor, the CAR T cells, and the normal hematopoietic cells in one patient with a secondary T-cell lymphoma.<\/p>\n The study included 724 patients who received T-cell therapies at the study institution. The researchers identified lethal T-cell lymphoma in a patient who received axicabtagene ciloleucel therapy for diffuse large B-cell lymphoma; deep profiling was performed on both lymphomas. Molecularly distinct immunophenotypes and genomic profiles were seen for each lymphoma; both were associated with DNMT3A<\/em> and TET2<\/em> mutant clonal hematopoiesis and were positive for Epstein-Barr virus. Use of multiple techniques did not indicate evidence of oncogenic retroviral integration.<\/p>\n “In our index case, despite comprehensive genetic profiling, we found no evidence for CAR T-cell vector integration into the T-cell lymphoma or evidence for CAR expression,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n